PROCEPT BioRoboticsPRCT +4.95%70 9-Day RSI is 43.11 as of Jun. 27, 2026. GuruFocus rates PRCT with a GF Score™ of 70/100 and a GF Value™ of $92.12 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 871 Medical Devices & Instruments companies, PROCEPT BioRobotics ranks better than 70.38% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
PROCEPT BioRobotics 9-Day RSI Related Terms
PRCT vs ALMR, AHCO, ENOV: 9-Day RSI Comparison
For the Medical Devices subindustry, PROCEPT BioRobotics's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROCEPT BioRobotics 9-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where PROCEPT BioRobotics's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROCEPT BioRobotics (PRCT) has a 9-Day RSI of 43.11 as of Jun. 27, 2026. According to the industry distribution chart, PROCEPT BioRobotics ranks #258 out of 871 companies in the Medical Devices & Instruments industry, placing it in the top 29.6%.
Is PROCEPT BioRobotics' 9-Day RSI too high?
PROCEPT BioRobotics' current 9-Day RSI is 43.11. The Medical Devices & Instruments industry median 9-Day RSI is 43.37. PROCEPT BioRobotics' value of 43.11 is 0.6% below this industry median. Based on the distribution chart, PROCEPT BioRobotics ranks #258 out of 871 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, PROCEPT BioRobotics has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' 9-Day RSI compare to ALMR and AHCO?
According to the Medical Devices & Instruments industry distribution chart, PROCEPT BioRobotics ranks #258 out of 871 companies for 9-Day RSI. This puts PROCEPT BioRobotics in the upper half of its industry. The industry median 9-Day RSI is 43.37. PROCEPT BioRobotics' value of 43.11 is 0.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Devices & Instruments company?
The median 9-Day RSI among Medical Devices & Instruments companies is 43.37, based on 871 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PROCEPT BioRobotics's current 9-Day RSI of 43.11 is 0.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median 9-Day RSI is 43.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROCEPT BioRobotics's current 9-Day RSI is 43.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is $92.12, compared to a current price of $22.56 — trading 75.5% below its estimated fair value. The current 9-Day RSI is 43.11 and 0.6% below the Medical Devices & Instruments industry median of 43.37. PROCEPT BioRobotics' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For PROCEPT BioRobotics (PRCT), the current 9-Day RSI is 43.11 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROCEPT BioRobotics (PRCT) Overvalued in 2026?
Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued.
The current stock price of $22.56 is trading 75.5% below its estimated GF Value™ of $92.12.
GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.
Key valuation signals for PRCT:
9-Day RSI: 43.11
GF Value™: $92.12 vs. price of $22.56 (75.5% below fair value)
Industry Position: 0.6% below the Medical Devices & Instruments median (#258 of 871)
No single metric tells the full story. See the PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
70GF Score
Get the complete analysis for PRCT
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRCT has been successfully added to your 